Table 3.
Demographical characteristics and comorbidities.
| Author | Date | N | Mean age | Age range | Male | N (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Comorbidities | Diabetes | Hypertension | Cardiovascular disease | COPD/lung disease | ||||||
| Burrer et al. | 04/2020 | 8945 | 42 | 16–>65 | 2464 (27.5%) | 1779 (19.9%) | N/A | N/A | N/A | N/A |
| Chu et al. | 03/2020 | 54 | 39 | 26–73 | 36 (66.7%) | N/A | N/A | N/A | N/A | N/A |
| Wei et al. | 04/2020 | 14 | 36 | 27–51 | 4 (28.6%) | 1 (7.7%) | 0 | 0 | 0 | 0 |
| Xing et al. | 03/2020 | 2 | 30 | 20–40 | 1 (50%) | N/A | N/A | N/A | N/A | N/A |
| Zhan et al. | 02/2020 | 23 | 55 | 29–72 | 17 (73.9%) | 5 (21.7%) | N/A | N/A | N/A | N/A |
| Marjolein et al. | 03/2020 | 1353 | 49 | 22–66 | 15 (1.1%) | N/A | N/A | N/A | N/A | N/A |
| Wang et al. | 04/2020 | 80 | 39 | N/A | 31 (38.7%) | N/A | 1 (1.2%) | 10 (12.5%) | 2 (2.5%) | 1 (1.2%) |
| Nguyen et al. | 05/2020 | 99,795 | 42 | N/A | 16,965 (17%) | N/A | 2495 (2.5%) | N/A | 1597 (1.6%) | 13,073 (13.1%) |
| Zheng et al. | 03/2020 | 2457 | N/A | N/A | 681 (27.7%) | N/A | N/A | N/A | N/A | N/A |
| Schwierzeck et al. | 04/2020 | 957 | 35 | N/A | 370 (38.7%) | N/A | N/A | N/A | N/A | N/A |
| Canova et al. | 04/2020 | 21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Ran et al. | 03/2020 | 72 | 31 | 21–66 | 22 (30.6%) | N/A | N/A | N/A | N/A | N/A |
| Lai et al. | 05/2020 | 110 | 36.5 | N/A | 31 (28.2%) | 14 (12.7%) | 1 (0.9%) | 12 (10.9%) | 0 (0%) | 2 (1.8%) |
| Chow et al. | 05/2020 | 48 | 43 | 22–79 | 11 (22.9%) | N/A | N/A | N/A | N/A | N/A |
| Tostmann et al. | 04/2020 | 803 | N/A | N/A | 19 (2.4%) | N/A | N/A | N/A | N/A | N/A |
| Reusken et al. | 03/2020 | 1097 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Heinzerling et al. | 04/2020 | 43 | 39 | 27–60 | 7 (16.3%) | N/A | N/A | N/A | N/A | N/A |
| Breazzano et al. | 04/2020 | 264 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Korth et al. | 05/2020 | 316 | N/A | N/A | 112 (35.4%) | N/A | N/A | N/A | N/A | N/A |
| Felice et al. | 05/2020 | 388 | N/A | N/A | N/A | 63 (16.2%) | N/A | N/A | N/A | N/A |
| McMichael et al. | 03/2020 | 50 | 43.5 | 21–79 | 12 (24%) | 18 (36%) | 5 (10%) | 4 (8%) | 4 (8%) | N/A |
| Jin et al. | 05/2020 | 103 | 35 | N/A | 39 (37.9%) | N/A | N/A | N/A | N/A | N/A |
| Cabasa et al. | 05/2020 | 1632 | 40.7 | 30–60 | 336 (20.6%) | 269 (16.5%) | N/A | N/A | N/A | N/A |
| Sun et al. | 03/2020 | 32 | 33.8 | 22−56 | 4 (12.5%) | N/A | N/A | N/A | N/A | N/A |
| Chen et al. | 05/2020 | 105 | 30 | 26−39.5 | 2 (1.9%) | N/A | N/A | N/A | N/A | N/A |
| Rivera-Izquierdo et al. | 06/2020 | 76 | 45.8 | N/A | 23 (30.3%) | N/A | 5 (6.6%) | 8 (10.5%) | N/A | 5 (6.6%) |
| Garzaro et al. | 05/2020 | 830 | 46 | N/A | 276 (33.2%) | N/A | N/A | N/A | N/A | N/A |
| Guo et al. | 05/2020 | 24 | 36.1 | 25−48 | 23 (95.8%) | N/A | 1 (4.2%) | N/A | N/A | N/A |
Abbreviations: COPD, chronic obstructive pulmonary disease; N/A, not available; N, number.